mercaptopurine has been researched along with mizoribine* in 6 studies
6 other study(ies) available for mercaptopurine and mizoribine
Article | Year |
---|---|
Immunosuppressive efficacy of mycophenolate mofetil when compared with azathioprine and mizoribine against peripheral lymphocytes from renal transplant recipients.
Mycophenolate mofetil is currently used instead of azathioprine in clinical transplantation. However, comparative studies for the immunosuppressive potency of anti-metabolites used for organ transplantation have not been well documented. We compared the pharmacological efficacy of mycophenolic acid (MPA), 6-meraputopurine (6-MP), and mizoribine (MZ) for inhibiting purine synthesis of peripheral blood mononuclear cells (PBMCs) in vitro by a mitogen assay procedure. PBMCs were obtained from 18 renal transplant recipients before operation and 18 healthy subjects. The inhibitory efficacy of 6-MP against concanavalin A-induced PBMC blastogenesis exhibited large variations between subjects in both recipients and healthy subjects. In contrast, the pharmacological efficacy of MPA on PBMC blastogenesis showed the smallest inter-individual variation of all the purine synthesis inhibitors examined. Furthermore, the effects of MPA were almost similar in the recipients and healthy subjects. The pharmacological efficacy of MZ against PBMC blastogenesis was weaker than that of the other two agents and the inter-individual variation of MZ IC50 against PBMCs of the patients was larger than that of MZ IC50 against PBMCs of healthy subjects. Reproducible immunosuppressive efficacy of MPA compared with other purinesynthesis inhibitors could be expected from the viewpoint of MPA pharmacodynamics against PBMCs in renal transplantation. Topics: Adult; Azathioprine; Case-Control Studies; Female; Humans; Immunosuppressive Agents; In Vitro Techniques; Kidney Transplantation; Lymphocyte Activation; Lymphocytes; Male; Mercaptopurine; Middle Aged; Mycophenolic Acid; Nucleic Acid Synthesis Inhibitors; Ribonucleosides | 2005 |
IMP dehydrogenase inhibitors as immunomodulators.
IMP dehydrogenase is a key enzyme in the de novo pathway of purine biosynthesis and is responsible for catalyzing the first step in the formation of guanine ribonucleotides from inosine monophosphate. Mizoribine, an immunosuppressive agent in wide-spread clinical use in Japan, has been demonstrated to inhibit this enzyme. We have investigated the effects of mizoribine on human T cell activation. Stimulation of purified human peripheral blood T lymphocytes with phorbol ester and ionomycin leads to a five-fold increase in guanine ribonucleotide levels over 72 hours. The addition of mizoribine to these cultures at concentrations that are achieved in vivo leads to a dose-dependent inhibition of proliferation and concomitant 50% decrease in guanine ribonucleotide levels, an effect that is reversible with the addition of guanosine, which repletes the GTP pool. Similar effects are seen with direct stimulation via the CD3/T cell receptor complex. Inhibition of proliferation occurs at the G1/S interface of the cell cycle and is additive to that produced by cyclosporine. In order to determine whether inhibition of IMP dehydrogenase is a common mechanism of immunosuppression for drugs such as azathioprine and 6-mercaptopurine that interfere with purine biosynthesis, we compared the effects of these agents on the metabolism of purified T lymphocytes. The results of these studies demonstrate that mizoribine and mycophenolic acid, a highly specific inhibitor of IMP dehydrogenase, inhibit proliferation directly by the depletion of guanine ribonucleotides; 6-mercaptopurine, on the other hand, has a mixed effect on adenine and guanine ribonucleotide pools, whereas azathioprine inhibits proliferation by a mechanism completely independent of its effects on the purine metabolic pathway. We conclude from these studies that inhibitors of IMP dehydrogenase have potential as specific immunosuppressive agents. Topics: Azathioprine; Cell Cycle; Cells, Cultured; Guanosine Triphosphate; Humans; Immunosuppressive Agents; IMP Dehydrogenase; Lymphocyte Activation; Mercaptopurine; Ribonucleosides; T-Lymphocytes | 1993 |
Mutagenicity of combined immunosuppressants.
Topics: Cyclosporine; Drug Interactions; Graft Survival; Humans; Immunosuppressive Agents; In Vitro Techniques; Lymphocytes; Mercaptopurine; Mutagens; Ribonucleosides; Sister Chromatid Exchange | 1993 |
Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on T lymphocyte proliferation and purine ribonucleotide metabolism.
The immunosuppressive drug mizoribine has been demonstrated to inhibit T lymphocyte proliferation by depleting these cells of guanine ribonucleotides as a consequence of inhibiting the enzyme inosine monophosphate (IMP) dehydrogenase. Because the immunosuppressive agents azathioprine and 6-mercaptopurine (6MP) are both converted to the IMP analog 6-thio-IMP, we postulated that these drugs might inhibit T cell activation and/or proliferation by a similar mechanism. Incubation of isolated peripheral blood T cells with either mizoribine or the selective IMP dehydrogenase inhibitor mycophenolic acid caused a dose-dependent inhibition of T cell proliferation, which was reversible with the addition of 50 microM guanosine to replete guanine ribonucleotide pools. In contrast, guanosine exacerbated the inhibition of proliferation induced by azathioprine and restored proliferation at IC50 concentrations of 6MP by only 10%. Complete restoration of proliferation in the presence of 6MP, but not azathioprine, was achieved with the addition of adenine. The inhibitory effects of azathioprine, as well as those of mizoribine, 6MP, and mycophenolic acid, were identical in cells stimulated with antibody to the T cell receptor and in cells stimulated with phorbol ester and ionomycin. We conclude from these studies that mizoribine selectively inhibits guanine ribonucleotide formation in purified T cells, whereas the effect of 6MP appears to be more dependent on adenine ribonucleotide depletion. Azathioprine, on the other hand, inhibits proliferation by a mechanism independent of purine ribonucleotide depletion. None of these agents inhibits T cell proliferation by interfering with signal transduction mediated by the T cell receptor. Inhibition of guanine ribonucleotide biosynthesis appears to be a novel and perhaps more selective mechanism of inhibiting T cell proliferative responses after T cell activation. Topics: Azathioprine; Cell Division; Guanosine; Humans; Immunosuppressive Agents; Ionomycin; Lymphocyte Activation; Mercaptopurine; Mycophenolic Acid; Purine Nucleotides; Receptors, Antigen, T-Cell; Ribonucleosides; Signal Transduction; T-Lymphocytes; Tetradecanoylphorbol Acetate | 1992 |
Mutagenicity of cyclosporine against human cells.
Topics: Cells, Cultured; Cyclosporins; Humans; Immunosuppressive Agents; Lymphocytes; Mercaptopurine; Methotrexate; Mutagenicity Tests; Mutagens; Ribonucleosides; Sister Chromatid Exchange | 1987 |
Anti-arthritic activity of bredinin, an immunosuppressive agent.
Topics: Animals; Anti-Bacterial Agents; Arthritis; Arthritis, Experimental; Female; Hindlimb; Immunosuppressive Agents; Mercaptopurine; Rats; Ribonucleosides; Structure-Activity Relationship | 1977 |